*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information
8 In June 2021, semaglutide received approval under the name Wegovy at a higher dose (2.4 mg weekly) for chronic weight management in adults with obesity or overweight conditions
Safety Profile and Reported Side Effects The most common side effects are gastrointestinal nausea, vomiting, and diarrhoea alongside a modest increase in resting heart rate
Participants must work within their professional regulatory framework and local legislation.
Make sure to file your malpractice claim as soon as youre able to
Vitamin B12 is vital for making healthy red blood cells